In vivo effects of two novel alkylating benzodiazepines, irazepine and kenazepine

Evan F. Williams, Kenner C. Rice, Mariena Mattson, Steven M. Paul, Phil Skolnick

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Intracerebroventricular administration of the alkylating benzodiazepines irazepine or kenazepine (20 nmol) resulted in a complete protection against convulsant doses of pentylenetetrazole (PTZ) for at least one hour, and a statistically significant protection for at least two and four hours, respectively. In contrast, administration of the non-alkylating parent benzodiazepine Ro-7/1986 or diazepam (20-60 nmol) resulted in no detectable anticonvulsant effects at fifteen minutes post-injection, the earliest interval examined. These results suggest that alkylating benzodiazepines which bind to brain benzodiazepine receptors in a non-competitive (covalent) fashion in vitro may exert a long lasting anticonvulsant effect by a similar mechanism.

Original languageEnglish
Pages (from-to)487-491
Number of pages5
JournalPharmacology, Biochemistry and Behavior
Issue number4
StatePublished - Apr 1981


  • Benzodiazepine receptors
  • Irazepine
  • Kenazepine
  • Pentylenetetrazole


Dive into the research topics of 'In vivo effects of two novel alkylating benzodiazepines, irazepine and kenazepine'. Together they form a unique fingerprint.

Cite this